Hepatokines as a Link between Obesity and Cardiovascular Diseases - PubMed (original) (raw)

Review

Hye Jin Yoo et al. Diabetes Metab J. 2015 Feb.

Abstract

Non-alcoholic fatty liver disease, which is considered a hepatic manifestation of metabolic syndrome, independently increases the risks of developing cardiovascular disease (CVD) and type 2 diabetes mellitus. Recent emerging evidence suggests that a group of predominantly liver-derived proteins called hepatokines directly affect the progression of atherosclerosis by modulating endothelial dysfunction and infiltration of inflammatory cells into vessel walls. Here, we summarize the role of the representative hepatokines fibroblast growth factor 21, fetuin-A, and selenoprotein P in the progression of CVD.

Keywords: Fetuin-A; Fibroblast growth factor 21; Hepatokines; Non-alcoholic fatty liver disease; Selenoprotein P.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1

Fig. 1. Underlying mechanism connecting non-alcoholic fatty liver disease (NAFLD) to cardiovascular disease (CVD). LDL, low density lipoprotein; HDL, high density lipoprotein; hsCRP, high-sensitivity C-reactive protein; PAI-1, plasminogen activator inhibitor-1; FGF-21, fibroblast growth factor 21.

References

    1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344. - PubMed
    1. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33:1190–1200. - PubMed
    1. Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014;34:1155–1161. - PubMed
    1. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230:258–267. - PubMed
    1. Akabame S, Hamaguchi M, Tomiyasu K, Tanaka M, Kobayashi-Takenaka Y, Nakano K, Oda Y, Yoshikawa T. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT) Circ J. 2008;72:618–625. - PubMed

Publication types

LinkOut - more resources